270 related articles for article (PubMed ID: 29157398)
1. New Advances in Disease-Modifying Therapies for Relapsing and Progressive Forms of Multiple Sclerosis.
Vidal-Jordana A
Neurol Clin; 2018 Feb; 36(1):173-183. PubMed ID: 29157398
[TBL] [Abstract][Full Text] [Related]
2. Antibody Therapies for Progressive Multiple Sclerosis and for Promoting Repair.
Havla J; Hohlfeld R
Neurotherapeutics; 2022 Apr; 19(3):774-784. PubMed ID: 35289375
[TBL] [Abstract][Full Text] [Related]
3. Ocrelizumab (Ocrevus) for MS.
Med Lett Drugs Ther; 2017 Jun; 59(1523):98-101. PubMed ID: 28609424
[No Abstract] [Full Text] [Related]
4. Disease-modifying treatments for progressive multiple sclerosis.
Comi G
Mult Scler; 2013 Oct; 19(11):1428-36. PubMed ID: 24062415
[TBL] [Abstract][Full Text] [Related]
5. New Drug For Multiple Sclerosis.
Aschenbrenner DS
Am J Nurs; 2017 Jul; 117(7):22. PubMed ID: 28644283
[No Abstract] [Full Text] [Related]
6. Progressive Multiple Sclerosis.
Ontaneda D
Continuum (Minneap Minn); 2019 Jun; 25(3):736-752. PubMed ID: 31162314
[TBL] [Abstract][Full Text] [Related]
7. Intramuscular IFNß-1a in multiple sclerosis: 'no proof of effectiveness' or 'proof of no effectiveness'?
Messori A; Fadda V; Maratea D; Trippoli S
Eur J Neurol; 2013 Dec; 20(12):e131. PubMed ID: 24433477
[No Abstract] [Full Text] [Related]
8. Laquinimod in the treatment of relapsing remitting multiple sclerosis.
Hainke U; Thomas K; Ziemssen T
Expert Opin Drug Metab Toxicol; 2016 Jun; 12(6):701-9. PubMed ID: 27089834
[TBL] [Abstract][Full Text] [Related]
9. Novel therapeutic options for multiple sclerosis.
Curtin F; Hartung HP
Expert Rev Clin Pharmacol; 2014 Jan; 7(1):91-104. PubMed ID: 24325127
[TBL] [Abstract][Full Text] [Related]
10. Comment on the letter by Messori et al. (European Journal of Neurology 2013; 20: e131).
Sormani MP
Eur J Neurol; 2014 Oct; 21(10):e84. PubMed ID: 25209064
[No Abstract] [Full Text] [Related]
11. Update on disease-modifying therapies for multiple sclerosis.
Vargas DL; Tyor WR
J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoids and B cells: emerging targets for treating progressive multiple sclerosis.
Giovannoni G
Mult Scler; 2011 Mar; 17(3):259-61. PubMed ID: 21362756
[No Abstract] [Full Text] [Related]
13. Multiple Sclerosis: Epidemiologic, Clinical, and Therapeutic Aspects.
Vidal-Jordana A; Montalban X
Neuroimaging Clin N Am; 2017 May; 27(2):195-204. PubMed ID: 28391781
[TBL] [Abstract][Full Text] [Related]
14. Ocrelizumab: a B-cell depleting therapy for multiple sclerosis.
Jakimovski D; Weinstock-Guttman B; Ramanathan M; Kolb C; Hojnacki D; Minagar A; Zivadinov R
Expert Opin Biol Ther; 2017 Sep; 17(9):1163-1172. PubMed ID: 28658986
[TBL] [Abstract][Full Text] [Related]
15. Multiple sclerosis: Is there a safe time to discontinue therapy in MS?
Freedman MS
Nat Rev Neurol; 2016 Dec; 13(1):10-11. PubMed ID: 28028316
[No Abstract] [Full Text] [Related]
16. Occasional essay: Multiple sclerosis in the digital age: 'seeing through a glass darkly'.
Compston A
J Neurol Neurosurg Psychiatry; 2020 Oct; 91(10):1017-1023. PubMed ID: 32709701
[No Abstract] [Full Text] [Related]
17. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
[TBL] [Abstract][Full Text] [Related]
18. Antibodies against CD20 (rituximab) for treating multiple sclerosis: US20100233121.
Taupin P
Expert Opin Ther Pat; 2011 Jan; 21(1):111-4. PubMed ID: 21155688
[TBL] [Abstract][Full Text] [Related]
19. The balance of pro-inflammatory and trophic factors in multiple sclerosis patients: effects of acute relapse and immunomodulatory treatment.
Lindquist S; Hassinger S; Lindquist JA; Sailer M
Mult Scler; 2011 Jul; 17(7):851-66. PubMed ID: 21561957
[TBL] [Abstract][Full Text] [Related]
20. Moving Towards a Cure for MS: Increased Immunosuppression and Striving for No Evidence of Disease Activity (NEDA).
Wong B; Cahill J; Rizvi S
R I Med J (2013); 2018 Mar; 101(2):26-29. PubMed ID: 29490321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
